盐酸氯丙嗪_MSDS_用途_密度_盐酸氯丙嗪CAS号【69-09-0】

Chlorpromazine Hydrochloride是D2,5HT2A,钾通道和钠通道的拮抗剂。 Chlorpromazine与 D2 和 5HT2A 结合的 Ki 分别为363 nM和8.3 nM。

[ 描述 ]:

Chlorpromazine Hydrochloride是D2,5HT2A,钾通道和钠通道的拮抗剂。 Chlorpromazine与 D2 和 5HT2A 结合的 Ki 分别为363 nM和8.3 nM。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体

信号通路 >> 神经信号通路 >> 5-HT受体

信号通路 >> 自噬 >> 自噬

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 多巴胺受体

信号通路 >> 神经信号通路 >> 多巴胺受体

信号通路 >> 跨膜转运 >> 钾通道

信号通路 >> 跨膜转运 >> 钠通道

研究领域 >> 神经疾病

[ 靶点 ]

Ki: 363 nM (dopamine D2 receptor), 8.3 nM (5-HT2A receptor)[4]

[体外研究]

氯丙嗪(3,10,20,40和60μM)以浓度依赖性方式降低hNav1.7的峰值电流,IC50为25.9μM,Hill系数为2.3。氯丙嗪(25μM)对hNav1.7电流产生强烈的使用依赖性抑制作用。氯丙嗪阻断hNav1.7通道,不依赖于钙调蛋白[1]。氯丙嗪阻断HERG钾通道,IC50值为21.6μM,Hill系数为1.11。氯丙嗪(1,10,100μM)以浓度依赖性方式阻断非洲爪蟾卵母细胞中表达的HERG钾通道。氯丙嗪在激活状态下阻断HERG钾通道[5]。

[体内研究]

氯丙嗪(2 mg/kg,ip)诱导的神经行为异常(NAs)的特征是小鼠的僵住行为显着增加,自发活动反应时间延长[2]。在大鼠治疗的第5天和第10天,氯丙嗪(1或5 mg/kg,i,p。)可防止氯胺酮(KET)增加δ和γ-高谱带的平均光谱功率[3]。

[动物实验]

将体重18-25g的成年小鼠（8-10周龄）分成5组，每组6只小鼠。治疗方案如下：第1组，对照（生理盐水：NS，10mL / kg ip）;第2组，氯丙嗪（CPZ，2 mg / kg ip）;第3组，溴隐亭（BMC，2.5 mg / kg sc）;第4组：氨氯地平（AML，1mg / kg sc）;第5组，BMC（2.5mg / kg sc）+ AML（1mg / kg）。用BMC或AML或其组合治疗的动物也在30分钟后（ip）接受氯丙嗪。对动物进行各种测试，包括用于强直性昏厥的金属棒测试和用于运动评估和敏捷性的自发活动轮以及高架十字迷宫，孔板，Y-迷宫，运动活动的开放场测试和探索行为。 18小时后通过颈椎脱位使动物安乐死。解剖脑，在缓冲液（pH 7.6）中漂洗并用Teflon匀浆并用于评估脂质过氧化，还原型谷胱甘肽，超氧化物歧化酶和过氧化氢酶。

[参考文献]

[1]. Lee SJ, et al. Mechanism of inhibition by chlorpromazine of the human pain threshold sodium channel, Nav1.7. Neurosci Lett. 2017 Feb 3;639:1-7

[2]. Kale OE, et al. Amlodipine, an L-type calcium channel blocker, protects against chlorpromazine-induced neurobehavioural deficits in mice. Fundam Clin Pharmacol. 2017 Jan 19

[3]. Sampaio LR, et al. Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats. J Psychiatr Res. 2017 Mar;86:73-82

[4]. Suzuki H, et al. Comparison of the anti-dopamine D? and anti-serotonin 5-HT(2A) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. J Psychopharmacol. 2013 Apr;27(4):396-400

[5]. Thomas, D., et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol, 2003. 139(3): p. 567-74.

[相关活性小分子]

[ 密度 ]:
1.077 g/cm3 (15 C)

[ 沸点 ]:
450.1ºC at 760 mmHg

[ 熔点 ]:
192-196°C

[ 分子式 ]:
C₁₇H₂₀Cl₂N₂S

[ 分子量 ]:
355.325

[ 精确质量 ]:
354.072418

[ PSA ]:
31.78000

[ LogP ]:
5.76140

[ 外观性状 ]:
奶油色-白色结晶粉末

[ 折射率 ]:
1.4436 (20ºC)

[ 储存条件 ]:
库房低温,通风,干燥,与食品原料分开存放

[ 稳定性 ]:
Stable. Combustible. Incompatible with strong oxidizing agents. Air and light sesnsitive.

[ 水溶解性 ]:
>=10 g/100 mL at 24 ºC

详细MSDS(安全技术说明书)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: SO1750000

CHEMICAL NAME :: Phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-, monohydrochloride

CAS REGISTRY NUMBER :: 69-09-0

LAST UPDATED :: 199710

DATA ITEMS CITED :: 54

MOLECULAR FORMULA :: C17-H19-Cl-N2-S.Cl-H

MOLECULAR WEIGHT :: 355.35

WISWESSER LINE NOTATION :: T C666 BN ISJ B3N1&1 EG &GH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 6071 ug/kg

TOXIC EFFECTS :: Reproductive - Paternal Effects - other effects on male

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 18 mg/kg

TOXIC EFFECTS :: Reproductive - Paternal Effects - other effects on male

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 6 mg/kg

TOXIC EFFECTS :: Behavioral - anorexia (human) Gastrointestinal - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 35 gm/kg/16Y-I

TOXIC EFFECTS :: Behavioral - rigidity (including catalepsy) Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - respiratory stimulation

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 1786 ug/kg/2D-I

TOXIC EFFECTS :: Behavioral - irritability Lungs, Thorax, or Respiration - respiratory stimulation Skin and Appendages - sweating

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 822 ug/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - excitement Cardiac - pulse rate increase, without fall in BP

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 145 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LC50 - Lethal concentration, 50 percent kill

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 40 mg/m3/2H

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 62 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 90 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 135 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - rigidity (including catalepsy) Behavioral - alteration of classical conditioning

TYPE OF TEST :: LC50 - Lethal concentration, 50 percent kill

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 40 mg/m3/2H

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 92200 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 420 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 20 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Primate - monkey

DOSE/DURATION :: >30 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - muscle weakness Behavioral - rigidity (including catalepsy)

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 5 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 109 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 420 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Bird - chicken

DOSE/DURATION :: 160 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Bird - chicken

DOSE/DURATION :: 28 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 900 mg/kg/30D-I

TOXIC EFFECTS :: Related to Chronic Data - changes in ovarian weight Related to Chronic Data - changes in uterine weight

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 50 mg/kg/5D-I

TOXIC EFFECTS :: Related to Chronic Data - changes in ovarian weight Related to Chronic Data - changes in uterine weight

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 300 mg/kg

SEX/DURATION :: female 6-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 50 mg/kg

SEX/DURATION :: female 7-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 250 mg/kg

SEX/DURATION :: female 7-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 350 mg/kg

SEX/DURATION :: female 7-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1980 mg/kg

SEX/DURATION :: male 4 week(s) pre-mating female 4 week(s) pre-mating - 3 week(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 2500 ug/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 25 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 100 mg/kg

SEX/DURATION :: female 14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 100 mg/kg

SEX/DURATION :: female 14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - gastrointestinal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 50 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 12 mg/kg

SEX/DURATION :: female 12-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 24 mg/kg

SEX/DURATION :: female 17-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - postpartum Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 12 mg/kg

SEX/DURATION :: female 12-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - behavioral

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 24 mg/kg

SEX/DURATION :: female 17-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 125 mg/kg

SEX/DURATION :: male 5 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 300 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 300 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - eye/ear

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 150 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 21 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 10 mg/kg

SEX/DURATION :: female 3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - other effects to embryo

MUTATION DATA

TEST SYSTEM :: Rodent - rat

DOSE/DURATION :: 25 mg/kg

REFERENCE :: DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 9,41,1986 *** REVIEWS *** TOXICOLOGY REVIEW JMSCA9 Journal of Mental Science. (London, UK) V.4-108, 1857-1962. For publisher information, see BJPYAJ. Volume(issue)/page/year: 106,755,1960 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M1050 No. of Facilities: 830 (estimated) No. of Industries: 2 No. of Occupations: 3 No. of Employees: 905 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M1050 No. of Facilities: 188 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 3661 (estimated) No. of Female Employees: 1936 (estimated)

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301-H330

[ 警示性声明 ]:
P260-P284-P301 + P310-P310

[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T+

[ 风险声明 (欧洲) ]:
R25

[ 安全声明 (欧洲) ]:
S28-S36/37-S45

[ 危险品运输编码 ]:
UN 2811 6.1/PG 1

[ WGK德国 ]:
3

[ RTECS号 ]:
SO1750000

[ 包装等级 ]:
III

[ 危险类别 ]:
6.1(b)

[ 海关编码 ]:
2932999099

详细合成路线

盐酸氯丙嗪上游产品

盐酸氯丙嗪下游产品

由2-氯吩噻嗪[92-39-7]缩合、成盐而得。1.缩合在反应锅中加入2-氯吩噻嗪和甲苯，再加入氢氧化钠，搅拌加热回流，脱除水分，在110℃滴加1-氯-3-二甲胺基丙烷的甲苯溶液，将反应物减压回收甲苯，即得氯丙嗪，C17H19CIN2S，[50-53-3]。2.成盐将氯丙嗪和异丙醇搅拌加热至40℃，通入干燥的氯化氢至pH4-5，即成盐得到盐酸氯丙嗪。

[ 海关编码 ]: 2934300000

[ 中文概述 ]:
2934300000. 含一个吩噻嗪环系的化合物(吩噻嗪环系不论是否氢化,化合物未经进一步稠合的 ). 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2934300000. other compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells.

Nat. Commun. 6 , 6240, (2015)

Epstein-Barr virus (EBV) is implicated as an aetiological factor in B lymphomas and nasopharyngeal carcinoma. The mechanisms of cell-free EBV infection of nasopharyngeal epithelial cells remain elusiv...

Direct cellular delivery of human proteasomes to delay tau aggregation.

Nat. Commun. 5 , 5633, (2014)

The 26S proteasome is the primary machinery that degrades ubiquitin (Ub)-conjugated proteins, including many proteotoxic proteins implicated in neurodegeneraton. It has been suggested that the elevati...

Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin.

Int. J. Pharm. 478(2) , 745-52, (2015)

Inhibitors against multidrug resistance (MDR) efflux transporters have failed in most clinical settings due to unfavorable pharmacokinetic interactions with co-administered anti-cancer drug and their ...

更多文献

公司名：上海化源世纪贸易有限公司

区域：上海市普陀区

价格：

联系人：徐经理

产品详情：盐酸氯丙嗪

公司名：上海吉至生化科技有限公司

区域：上海市奉贤区

价格：
￥328.0/25g ￥108.0/5g

联系人：刘佳

产品详情：盐酸氯丙嗪

公司名：上海源溪生物科技有限公司

区域：上海市浦东新区

价格：
￥需询单/1g

联系人：赖经理

产品详情：Chlorpromazine HCl

公司名：上海阿拉丁生化科技股份有限公司

区域：上海市浦东新区

价格：
￥873.9/100g ￥31.9/1g ￥262.9/25g ￥95.9/5g

联系人：阿拉丁

产品详情：盐酸氯丙嗪

公司名：湖北魏氏化学试剂股份有限公司

区域：武汉市洪山区

价格：
￥需询单/1kg

联系人：张栋

产品详情：盐酸氯丙嗪

查看所有供应商请点击：

盐酸氯丙嗪供应商

盐酸氯丙嗪-说明书-作用功效-盐酸氯丙嗪片副作用

2019-01-06 16:51:53

导读：盐酸氯丙嗪是吩噻类药物中的代表性药物。对中枢神经系统，小剂量有安定作用，大剂量连续使用有抗精神病作用，本品抑制丘脑下体温调节中枢，使体温随环境温度升降，配合其他药物，使体温降至正常体温之下，代谢降低，主要用于抗精神病、加强催眠剂、麻醉剂、镇痛剂及抗惊厥剂的作用。又可用于对呕吐和顽固性呃逆的镇...

盐酸氯丙嗪

盐酸氯丙嗪用途

盐酸氯丙嗪名称

盐酸氯丙嗪生物活性

盐酸氯丙嗪物理化学性质